Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance

Cancer Letters

Volumn 107, Issue 1, 1996, Pages 117-123

  Hotta, Tsukasa ^a   Tanimura, Hiroshi ^a   Yamaue, Hiroki ^a   Iwahashi, Makoto ^a   Tani, Masaji ^a   Tsunoda, Takuya ^a   Noguchi, Kohei ^a   Mizobata, Shizuma ^a   Terasawa, Hiroshi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cepharanthine; Doxorubicin; Multidrug resistance; P glycoprotein; Tamoxifen

Indexed keywords

CEPHARANTHINE; DOXORUBICIN; GLYCOPROTEIN P; TAMOXIFEN;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL;

EID: 0030271654     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04358-3     Document Type: Article

References (28)

1. [1] Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem., 62, 385-427.
2. [2] Callaghan, R. and Higgins, C.F. (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein, Br. J. Cancer, 71, 294-299.
3. [3] Leonessa, F., Jacobson, M., Boyle, B., Lippman, J., McGarvey, M. and Clarke, R. (1994) Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and Mr170,000 glycoprotein (gp170) binding studies, Cancer Res., 54, 441-447.
4. [4] Ramu, A., Glaubiger, D. and Fuks, Z. (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues, Cancer Res., 44, 4392-4395.
5. [5] Millward, M.J., Cantwell, B.M.J., Lien, E.A., Carmichael, J. and Harris, A.L. (1992) Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance, Eur. J. Cancer, 28A, 805-810.
6. [6] Millward, M.J., Lien, E.A., Robinson, A. and Cantwell, B.M.J. (1994) High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator, Oncology, 51, 79-83.
7. [7] Stuart, N.S.A., Philip, P., Harris, A.L., Tonkin, K., Houlbrook, S., Kirk, J., Lien, E.A. and Carmichael, J. (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity: clinical effects and in vitro assessment in P-glycoprotein expressing cell lines, Br. J. Cancer, 66, 833-839.
8. [8] Trump, D.L., Smith, D.C., Ellis, P.G., Rogers, M.P., Schold, S.C., Winer, E.P., Panella, T.J., Jordan, V.C. and Fine, R.L. (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine, J. Natl. Cancer Inst., 84, 1811-1816.
9. [9] Shiraishi, N., Akiyama, S., Nakagawa, M., Kobayashi, M. and Kuwano, M. (1987) Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells, Cancer Res., 47, 2413-2416.
10. [10] Nagaoka, S., Kawasaki, S., Karino, Y., Sasaki, K. and Nakanishi, T. (1987) Modification of cellular efflux and cytotoxicity of adriamycin by biscoclaulin alkaloid in vitro, Eur. J. Cancer, 23, 1297-1302.
11. [11] Akiyama, S., Cornwell, M.M., Kuwano, M., Pastan, I. and Gottesman, M.M. (1987) Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog, Mol. Pharmacol., 33, 144-147.
12. [12] Akiyama, S., Yoshimura, A., Kikuchi, H., Sumizawa, T., Kuwano, M. and Tahara, Y. (1989) Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells, Mol. Pharmacol., 36, 730-735.
13. [13] Komiyama, S., Matsui, K., Kudoh, S., Nogae, I., Kuratomi, Y., Saburi, Y., Asoh, K., Kohno, K. and Kuwano, M. (1989) Establishment of tumor cell lines from a patient with head and neck cancer and their different sensitivities to anti-cancer agents, Cancer, 63, 675-681.
14. [14] Saito, T., Hikita, M., Kohno, K., Sato, S., Takano, H. and Kobayashi, M. (1992) Different sensitivities of human esophageal cancer cells to multiple anti-cancer agents and related mechanisms, Cancer, 70, 2402-2409.
15. [15] Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55-63.
16. [16] Carmichael, J., Mitchell, J.B., Degraff, W.G., Gamson, J., Gazdar, A.F., Johnson, B.E., Glatstein, E. and Minna, J.D. (1985) Chemosensitivity testing of human lung cancer cell lines using the MTT assay, Br. J. Cancer, 57, 540-547.
17. [17] Yamaue, H., Tanimura, H., Tsunoda, T., Tani, M., Iwahashi, M., Noguchi, K., Tamai, M., Hotta, T. and Arii, K. (1991) Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay, Eur. J. Cancer, 27, 1258-1263.
18. [18] Yamaue, H., Tanimura, H., Noguchi, K., Hotta, T., Tani, M., Tsunoda, T., Iwahashi, M., Tamai, M. and Iwakura, S. (1992) Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay, Br. J. Cancer, 66, 794-799.
19. [19] Webb, J.L. (1963) Effect of more than one inhibitor, antagonism, summation, and synergism. In: Enzyme and Metabolic Inhibitors, Vol. 1, pp. 488-512. Academic Press, New York.
20. [20] Durand, R.E. and Olive, P.L. (1981) Flow cytometry studies of intracellular adriamycin in single cells in vitro, Cancer Res., 41, 3489-3494.
21. [21] Salmon, S.E., Dalton, W.S., Grogan, T.M., Plezia, P., Lehnert, M., Roe, D.J. and Miller, T.P. (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as chemosensitizer, Blood, 78, 44-50.
22. [22] Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res., 41, 1967-1972.
23. [23] Slater, L.M., Sweet, P., Stupecky, M. and Gupta, S. (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro, J. Clin. Invest., 77, 1405-1408.
24. [24] Yahanda, A.M., Adler, K.M., Fisher, G.A., Brophy, N.A., Halsey, J., Hardy, R.I., Gosland, M.P., Lum, B.L. and Sikic, B.I. (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance, J. Clin. Oncol., 10, 1624-1634.
25. [25] Kirk, J., Houlbrook, S., Stuart, N.S.A., Stratford, I.J., Harris, A.L. and Carmichael, J. (1993) Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites, Eur. J. Cancer, 29A, 1152-1157.
26. [26] Kirk, J., Houlbrook, S., Stuart, N.S.A., Stratford, I.J., Harris, A.L. and Carmichael, J. (1993) Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by antioestrogens and their major metabolites, Br. J. Cancer, 67, 1189-1195.
27. [27] Ramu, A., Ramu, N. and Rosario, L.M. (1991) Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine, Biochem. Pharmacol., 41, 1455-1461.
28. [28] O'Brian, C.A., Liskamp, R.M., Solomon, D.H. and Weinstein, I.B. (1985) Inhibition of protein kinase C by tamoxifen, Cancer Res., 45, 2462-2465.